FLOVENT DISKUS POWDER

国家: 加拿大

语言: 英文

来源: Health Canada

有效成分:

FLUTICASONE PROPIONATE

可用日期:

GLAXOSMITHKLINE INC

ATC代码:

R03BA05

INN（国际名称）:

FLUTICASONE

剂量:

50MCG

药物剂型:

POWDER

组成:

FLUTICASONE PROPIONATE 50MCG

给药途径:

INHALATION

每包单位数:

60 DOSES

处方类型:

Prescription

治疗领域:

ADRENALS

產品總結:

Active ingredient group (AIG) number: 0124685001; AHFS:

授权状态:

CANCELLED POST MARKET

授权日期:

2015-10-09

产品特点

_2014-07-29/131-pristine-english-Flovent.doc _
_ _
_ _
_Page 1 of 49_
PRODUCT MONOGRAPH
PR
FLOVENT
® HFA
fluticasone propionate inhalation aerosol
50, 125, and 250 mcg/metered dose
PR
FLOVENT
® DISKUS
®
fluticasone propionate powder for inhalation
50, 100, 250, and 500 mcg/blister
Corticosteroid for Oral Inhalation
GlaxoSmithKline Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
www.gsk.ca
Date of Revision: July 29, 2014
Submission Control No: 174022
_©_
_2014. GlaxoSmithKline Inc. All rights reserved. _
_®_
_FLOVENT, DISKUS and BABYHALER are registered trademarks, used under
license by GlaxoSmithKline Inc. _
_®_
_AEROCHAMBER PLUS is a registered trademark of Trudell Medical
International _
_2014-07-29/131-pristine-english-Flovent.doc _
_ _
_ _
_Page 2 of 49_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
....................................................................................................9
DRUG INTERACTIONS
..................................................................................................13
DOSAGE AND ADMINISTRATION
..............................................................................14
OVERDOSAGE
................................................................................................................18
ACTION AND CLINICAL PHARMACOLOGY
............................................................18
STORAGE AND STABILITY
..........................................................................................19
SPECIAL HANDLING INSTRUCTI